Ectopic expression of clusterin/apolipoprotein J or Bcl-2 decreases the sensitivity of HaCaT cells to toxic effects of ropivacaine

Cell Research

Volumn 14, Issue 5, 2004, Pages 415-422

  Kontargiris, Evangelos ^a   Kolettas, Evangelos ^a   Vadalouca, Athina ^b   Trougakos, Ioannis P ^c   Gonos, Efstathios S ^c   Kalfakakou, Vasiliki ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c INSTITUTE OF BIOLOGY   (Greece)

Author keywords

Apoptosis; Bcl 2; Clusterin apolipoprotein j; Keratinocytes; Ropivacaine

Indexed keywords

AMIDE; CHAPERONE; CLU PROTEIN, HUMAN; CLUSTERIN; GLYCOPROTEIN; PROTEIN BCL 2; ROPIVACAINE;

APOPTOSIS; ARTICLE; CELL LINE; CELL PROLIFERATION; DRUG EFFECT; GENETICS; HUMAN; KERATINOCYTE; METABOLISM; RADIATION RESPONSE;

AMIDES; APOPTOSIS; CELL LINE; CELL PROLIFERATION; CLUSTERIN; DOSE-RESPONSE RELATIONSHIP, RADIATION; GLYCOPROTEINS; HUMANS; KERATINOCYTES; MOLECULAR CHAPERONES; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 16644394798     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/sj.cr.7290242     Document Type: Article

References (42)

1. O'Keeffe NJ, Healy TE. The role of new anesthetic agents. Pharmacol Ther 1999; 84:233-48.
2. Owen MD, Dean LS. Ropivacaine. Expert Opin Pharmacother 2000; 1: 325-36.
3. Martinsson T, Haegerstrand A, Dalsgaard CJ. Effects of ropivacaine on eicosanoid release from human granulocytes and endothelial cells in vitro. Inflamm Res 1997; 46:398-403.
4. Martinsson T, Oda T, Fernvik E, et al. Ropivacaine inhibits leukocyte rolling, adhesion and CD11b/CD18 expression. J Pharmacol Exp Ther 1997; 283:59-65.
5. Zhang XW, Thorlacious H. Inhibitory actions of ropivacaine on tumor necrosis factor-α induced leukocyte adhesion and tissue accumulation in vivo. Eur J Pharmacol 2000; 392:R1-3.
6. De Iuliis A, Zanatta L, Vincenti E, Galzigna L. Differences of ropivacaine and bupivacaine relevant to anti-inflammatory activity, platelet aggregation and antioxidant activity in vitro. Il Farmaco 2001; 56:153-57.
7. Di Padova M, Barbieri R, Fanciulli M, Arcuri E, Floridi A. Effect of local anesthetic ropivacaine on the energy metabolism of Ehrlich ascites tumor cells. Oncol Res1998; 10:491-8.
8. Scutari G, Marian M, Bindoli A, et al. Mitochondrial effects of L-ropivacaine, a new local anesthetic. Biochem Pharmacol 1998; 56:1633-7.
9. Kim M, Lee YS, Mathews HL, Wurster RD. Induction of apoptotic cell death in a neuroblastoma cell line by dibucaine. Exp Cell Res 1997; 231:235-41.
10. Arita K, Utsami T, Kato A, et al. Mechanism of dibucaine-induced apoptosis in promyelocytic leukemia cells (HL-60). Biochem Pharmacol 2000; 60:905-15.
11. Nakamura K, Kido H, Morimoto Y, et al. Prilocaine induces apoptosis in osteoblastic cells. Can J Anaesth 1999; 46:476-82.
12. Martinsson T, Haegerstrand A, Dalsgaard, CJ. Ropivacaine and lidocaine inhibits proliferation of non-transformed cultured adult human fibroblasts, endothelial cells and keratinocytes. Agents Actions 1993; 40: 78-85.
13. 2 cytotoxicity and DNA strand breakage in L1210 and human A-253 cells. Cancer Res 1985; 45:2103-9.
14. Bisla K, Tanelian DL. Concentration-dependent effects of lidocaine on corneal epithelial wound healing. Invest Opthalmol Vis Sci 1992; 33:3029-33.
15. Martinsson T. Ropivacaine inhibits serum-induced proliferation of colon adenocarcinoma cells in vitro. J Pharmacol Exp Ther 1999; 288:660-4.
16. Cory S, Adams JM. Regulation of the cellular life-or-death switch. Nat Rev Cancer 2002; 2:647-56.
17. Jones SE, Jomary C. Clusterin. Int J Biochem Cell Biol 2002; 34:427-31.
18. Trougakos IP, Gonos ES. Clusterin/apolipoprotein J in human aging and cancer. Int J Biochem Cell Biol 2002; 34:1430-48.
19. Sensibar JA, Sutkowski DM, Raffo A, et al. Prevention of cell death induced by tumour necrosis factor-a in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin). Cancer Res 1995; 55:2431-7.
20. Sintich SM, Steinberg J, Kozlowski JM, et al. Cytotoxic sensitivity to tumor necrosis factor-alpha in PC3 and LNCaP prostatic cancer cells is regulated by extracellular levels of SGP-2 (clusterin). Prostate 1999; 39: 87-93.
21. Miyake H, Hara S, Zellweger T, Kamidono S, Gleave ME, Hara I. Acquisition of resistance to Fas-mediated apoptosis by overexpression of clusterin in human renal cell carcinoma cells. Mol Urol 2001; 5:105-11.
22. Dumont P, Chainiaux F, Eliaers F, et al. Overexpression of apolipoprotein J in human fibroblasts protects against cytotoxicity and premature senescence induced by ethanol and tetrbutylhydroperoxide. Cell Stress Chap 2002; 7:23-35.
23. Miyake H, Nelson C, Rennie PS, Gleave ME. Acquisition of chemoresistant phenotype by overexpression of the anti-apoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res 2000; 60: 2547-54.
24. Viard I, Wehrli P, Jornot L, et al. Clusterin gene expression mediates resistance to apoptotic cell death induced by heat shock and oxidative stress. J Invest Dermatol 1999; 112:290-6.
25. Miyake H, Chi KN, Gleave ME. Antisense TRPM-2 oligonucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res 2000; 6:1655-63.
26. Zellweger T, Miyake H, July LV, et al. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the anti-apoptotic gene clusterin. Neoplasia 2001; 3:360-7.
27. Miyake H, Hara I, Kamidono S, Gleave ME. Synergistic chemosensitization and inhibition of tumor growth and metastasis by the antisense oligonucleotide targeting clusterin gene in a human bladder cancer model. Clin Cancer Res 2001; 7:4245-52.
28. Petropoulou C, Trougakos IP, Kolettas E, Toussaint O, Gonos ES. Clusterin/apolipoprotein J is a novel biomarker of cellular senescence that does not affect the proliferative capacity of human diploid fibroblasts. FEBS Lett 2001; 509:287-97.
29. Odajima J, Matsumara I, Sonoyama J, et al. Full oncogenic activities of v-Src are mediated by multiple signaling pathways. Ras as an essential mediator for cell survival. J Biol Chem 2000; 275:24096-105.
30. 2-ceramide induces apoptosis in human squamous cell carcinoma cell line. Br J Dermatol 2000; 143:1154-63.
31. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-6.
32. Miyake H, Nelson C, Rennie PS, Gleave ME. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 2000; 60: 170-6.
33. Gleave ME, Miyake H, Zangemeister-Wittke U, Jansen B. Antisense therapy: current status in prostate cancer and other malignancies. Cancer Metastasis Rev 2002; 21:79-92.
34. Trougakos IP, So A, Jansen B, Gleave ME, Gonos ES. Silencing expression of the clusterin/apolipoprotein j gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res 2004; 64:1834-42.
35. Dumont P, Burton M, Chen QM, et al. Induction of replicative senescence biomarkers by sublethal oxidative stresses in normal human fibroblasts. Free Rad Biol Med 200; 28:361-73.
36. Calvo EL, Mallo GV, Fiedler F, et al. Clusterin overexpression in rat pancreas during the acute phase of pancreatitis and pancreatic development. Eur J Biochem 1998; 254:282-9.
37. French LE, Wohlwend A, Sappino AP, Tschopp J, Schiffereli JA. Human clusterin gene expression is confined to surviving cells during in vitro programmed cell death. J Clin Invest 1994; 93:877-84.
38. Miyake H, Hara I, Kamidono S, Gleave ME, Eto H. Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression. Oncol Rep 2003; 10:469-73.
39. Wu AJ, Park II, Zhaung L, Lee C. Response to a lethal dose of heat shock by a transient up-regulation of clusterin expression followed by down-regulation and apoptosis in prostate and bladder cancer cells. Prostate 2002; 53:277-85.
40. Koch-Brandt C, Morgans C. Clusterin: a role in cell survival in the face of apoptosis? Prog Mol Cell Biol 1996; 16: 130-49.
41. Li X, Massa PE, Hanidu A, et al. IKKα, IKKβ and NEMO/ IKKγ are each required for the NF-κB mediated inflammatory response program. J Biol Chem 2002; 277: 45129-40.
42. Li Q, Verma IM. NF-κB regulation in the immune system. Nature Rev Immunol 2002; 2:725-34.